Literature DB >> 25379135

Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer.

Zhigang Duan1, Guoqing Chen2, Liang Chen1, Rachael Stolzenberg-Solomon3, Stephanie J Weinstein3, Satu Mannisto4, Donna L White5, Demetrius Albanes3, Li Jiao5.   

Abstract

The soluble receptor for advanced glycation end-products (sRAGE) is shown to mitigate pro-inflammatory effects triggered by ligation of RAGE with N(ε)-carboxymethyl-lysine (CML)-AGE or other ligands. We examined the associations among host, lifestyle, and genetic determinants of CML-AGE or sRAGE and risk of pancreatic cancer in the prospective ATBC Study. We obtained baseline exposure information, data on serological and genetic biomarkers from 141 patients with pancreatic cancer and 141 subcohort controls. Stepwise linear and logistic regression models were used for data analysis. Multiple linear regression analyses showed that CML-AGE concentrations were independently inversely correlated with the minor allele of rs640742 of DDOST, physical activity, alcohol consumption, diastolic blood pressure (BP), and positively correlated with heart rate, serum sRAGE and HDL concentrations (P < 0.05). sRAGE concentrations were independently inversely correlated with the 82Ser allele of rs2070600 of RAGE, age, body mass index, heart rate, and serum HDL; and positively correlated with serum CML-AGE, sucrose consumption, and diastolic BP (P < 0.05). The minor allele of rs1035786 of RAGE was associated with reduced risk of pancreatic cancer (any T compared with CC: multivariate OR = 0.61, 95% CI: 0.38-0.98). We identified host metabolic profile, lifestyle and genetic factors that explained approximately 50% of variability of CML-AGE or sRAGE in Finnish men smokers. The association between RAGE SNPs and pancreatic cancer risk warrants further investigation.

Entities:  

Keywords:  Advanced glycation end-products; inflammation; metabolic syndrome; pancreatic cancer; sRAGE; single nucleotide polymorphism

Year:  2014        PMID: 25379135      PMCID: PMC4214263     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  53 in total

1.  Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects.

Authors:  Subrata K Biswas; Sonchita R Mudi; Forhadul H Mollah; Angelika Bierhaus; M Iqbal Arslan
Journal:  Diab Vasc Dis Res       Date:  2013-03-21       Impact factor: 3.291

2.  Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol.

Authors:  Y Al-Abed; T Mitsuhashi; H Li; J A Lawson; G A FitzGerald; H Founds; T Donnelly; A Cerami; P Ulrich; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

3.  Serum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: the Age, Gene/Environment Susceptibility-Reykjavik Study.

Authors:  Richard D Semba; Mary Frances Cotch; Vilmundur Gudnason; Gudny Eiríksdottir; Tamara B Harris; Kai Sun; Ronald Klein; Fridbert Jonasson; Luigi Ferrucci; Debra A Schaumberg
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

4.  Serum advanced glycation end products (AGEs) are associated with insulin resistance.

Authors:  Kathryn C B Tan; Sammy W M Shiu; Ying Wong; Xystus Tam
Journal:  Diabetes Metab Res Rev       Date:  2011-07       Impact factor: 4.876

5.  Genetic variation in the receptor for advanced glycation end-products (RAGE) gene and ischaemic stroke.

Authors:  S Olsson; K Jood
Journal:  Eur J Neurol       Date:  2012-12-17       Impact factor: 6.089

6.  Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

Authors:  Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

Review 7.  Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-03-11

8.  Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene.

Authors:  Anastasia Z Kalea; Nina Reiniger; Hojin Yang; Maria Arriero; Ann Marie Schmidt; Barry I Hudson
Journal:  FASEB J       Date:  2009-01-22       Impact factor: 5.191

9.  Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study.

Authors:  Haruki Momma; Kaijun Niu; Yoritoshi Kobayashi; Cong Huang; Masahiko Chujo; Atsushi Otomo; Hiroko Tadaura; Toshio Miyata; Ryoichi Nagatomi
Journal:  J Clin Endocrinol Metab       Date:  2013-11-25       Impact factor: 5.958

10.  N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.

Authors:  Khaled A Ahmed; Sekaran Muniandy; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2008-12-27       Impact factor: 3.114

View more
  8 in total

1.  Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.

Authors:  Tina E Brinkley; Xiaoyan Leng; Barbara J Nicklas; Stephen B Kritchevsky; Jingzhong Ding; Dalane W Kitzman; W Gregory Hundley
Journal:  Metabolism       Date:  2017-02-10       Impact factor: 8.694

2.  Genetic analysis of advanced glycation end products in the DHS MIND study.

Authors:  Jeremy N Adams; Laura M Raffield; Susan E Martelle; Barry I Freedman; Carl D Langefeld; J Jeffrey Carr; Amanda J Cox; Donald W Bowden
Journal:  Gene       Date:  2016-02-23       Impact factor: 3.688

Review 3.  The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease.

Authors:  Ravichandran Ramasamy; Alexander Shekhtman; Ann Marie Schmidt
Journal:  Expert Opin Ther Targets       Date:  2015-11-11       Impact factor: 6.902

4.  A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women.

Authors:  Donna L White; Ron C Hoogeveen; Liang Chen; Peter Richardson; Milan Ravishankar; Preksha Shah; Lesley Tinker; Thomas Rohan; Eric A Whitsel; Hashem B El-Serag; Li Jiao
Journal:  Cancer Med       Date:  2018-03-23       Impact factor: 4.452

Review 5.  Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism.

Authors:  Marine Serveaux-Dancer; Matthieu Jabaudon; Isabelle Creveaux; Corinne Belville; Raïko Blondonnet; Christelle Gross; Jean-Michel Constantin; Loïc Blanchon; Vincent Sapin
Journal:  Dis Markers       Date:  2019-02-04       Impact factor: 3.434

6.  Polymorphisms in Glyoxalase I Gene Are Not Associated with Glyoxalase I Expression in Whole Blood or Markers of Methylglyoxal Stress: The CODAM Study.

Authors:  Kim Maasen; Nordin M J Hanssen; Carla J H van der Kallen; Coen D A Stehouwer; Marleen M J van Greevenbroek; Casper G Schalkwijk
Journal:  Antioxidants (Basel)       Date:  2021-02-02

7.  Common variants in glyoxalase I do not increase chronic pancreatitis risk.

Authors:  Tom Kaune; Marcus Hollenbach; Bettina Keil; Jian-Min Chen; Emmanuelle Masson; Carla Becker; Marko Damm; Claudia Ruffert; Robert Grützmann; Albrecht Hoffmeister; Rene H M Te Morsche; Giulia Martina Cavestro; Raffaella Alessia Zuppardo; Adrian Saftoiu; Ewa Malecka-Panas; Stanislaw Głuszek; Peter Bugert; Markus M Lerch; Frank Ulrich Weiss; Wen-Bin Zou; Zhuan Liao; Peter Hegyi; Joost Ph Drenth; Jan Riedel; Claude Férec; Markus Scholz; Holger Kirsten; Andrea Tóth; Maren Ewers; Heiko Witt; Heidi Griesmann; Patrick Michl; Jonas Rosendahl
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

8.  Receptor for advanced glycation end-product rs1800624 polymorphism contributes to increase breast cancer risk: Evidence from a meta-analysis.

Authors:  Wei Zhang; Xiaowei Deng; Ruijun Tang; Hong Wang
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.